ArticleScientific reports2025
Optimal serum vitamin D3 levels are associated with lower osteoarthritis risk and better overall health in US adults.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To recommend serum Vitamin D3(VD3) levels for osteoarthritis patients and susceptible populations by analyzing the dose-effect relationship between VD3 and the risk of osteoarthritis(OA) and between life's essential 8 and VD3 in OA patients. This study analyzed the National Health and Nutrition Examination Survey (NHANES) 2007-2018 cross-sectional data, excluding incomplete cases. Weighted baselines were calculated, and multiple logistic regression was used to assess the VD3-OA risk relationship. Multiple linear regression explored the VD3-LE8 score association in general and OA populations. Curve associations were modeled with restricted cubic splines, followed by subgroup and sensitivity analysis, and segmented regression based on the spline outcomes. Of 18,107 participants, OA patients had higher VD3 (76.79 nmol/L) and lower LE8 (64.70) than normal participants (65.96 nmol/L, 70.02). VD3 levels (Q1-Q4) correlated with OA risks of 9.82%-19.77%. Higher VD3 increased OA risk (Estimate = 0.006, P < 0.0001 per 1nmol/L), but RCS and segmented regression showed a U-shaped association (cutoff: 41 nmol/L). In OA patients and normals, VD3 positively correlated with LE8 (Estimate = 0.035, P < 0.001 for per 1nmol/L), with a linear RCS relationship. Sensitivity analysis confirmed these results. Our findings reveal a U-shaped association between VD3 levels and the risk of osteoarthritis (OA), while a positive association between VD3 and LE8 score. Based on these observations, we recommend maintaining moderate serum VD3 levels, for both OA-susceptible individuals and patients to optimize its overall health benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.